Anti-TNF Induced Sarcoidosis-Like Disease in Rheumatoid Arthritis Patients: Review Cases from the RA UCLouvain Brussels Cohort
ConclusionsThis case highlights this rare paradoxical side effect and the variability of the clinical presentation. Further studies should analyze the immunopathology of such conditions. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 8, 2022 Category: Rheumatology Source Type: research
A Patient with Symmetrical Polyarthritis. The Value of Conventional Radiography for a Correct Diagnosis
We present a patient with peripheral symmetrical polyarthritis involving the small joints of the hands, diagnosed and treated as RA and we discuss the role of imaging, especially the use of CR as an initial screening tool for the evaluation of the articular manifestations and joint damage, and its further usefulness in order to reach a definitive correct diagnosis. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 3, 2022 Category: Rheumatology Source Type: research
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes
ConclusionsA considerable proportion of patients with RA attained the target of remission or LDA after 12 weeks of ETN treatment. Even beyond that timepoint, the proportion of patients achieving treatment targets continued to increase up to week 52.Trial RegistrationClinicalTrials.gov Identifier: NCT02486302. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 3, 2022 Category: Rheumatology Source Type: research
Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
AbstractCoronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of concern worldwide and a huge challenge for rheumatologists. Indeed, several antirheumatic drugs are currently used at different stages of COVID-19, such as several cytokine inhibitors and colchicine. Colchicine is one of the oldest medicines with potent anti-inflammat ory properties. In rheumatic diseases it is widely used for the treatment of gout, calcium pyrophosphate deposition disease, and familial Mediterranean fever. It is also used off-label in cardiology to treat atrial fibrillati...
Source: Rheumatology and Therapy - February 2, 2022 Category: Rheumatology Source Type: research
Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice
AbstractPsoriatic arthritis (PsA) is associated with a higher burden of co-morbidities such as obesity, cardiovascular disease, non-alcoholic fatty liver disease, inflammatory eye disease, inflammatory bowel disease, skin cancer and depression compared to the general population. In the last 20 years, the therapeutic options for PsA have increased exponentially with the availability of tumor necrosis factor-alpha (TNF) inhibitors, interleukin (IL)-17 inhibitors, IL-12/23 inhibitors and Janus kinases/signal transducer and activator of transcription proteins (JAK/STAT) inhibitors. The arti cular and extra-articular manifest...
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Comparative Effectiveness of Azathioprine Versus Cyclosporine as an Initial Treatment for Idiopathic Inflammatory Myopathies: A Population-Based Observational Study
ConclusionsThe effectiveness of AZA and CsA as initial treatments for the management of IIM was comparable. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Benefit –Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
ConclusionIn patients with active RA despite MTX use, UPA demonstrated an incremental achievement of clinical outcomes compared to ADA together with a similar profile of AESIs with ADA (with the exception of herpes zoster). (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study
ConclusionsGB242 demonstrated equivalent efficacy to INF at week 30. Moreover, GB242 was well tolerated, with a similar immunogenicity and safety profile comparable to INF. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Burden, Treatment Patterns and Unmet Needs of Osteoarthritis in Dubai: a Retrospective Analysis of the Dubai Real-World Claims Database
ConclusionOsteoarthritis imposes a substantial healthcare and economic burden in the UAE. The study findings elucidate the unmet need among patients with difficult-to-treat OA and inform development of new therapeutics to alleviate their burden. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower ® Registry
ConclusionsDigital remote patient monitoring presents an opportunity to detect and address medication tolerability in real time. Using a novel study design to control for between-person confounding, the magnitude of nausea and fatigue experienced by participants with RA and PsA temporally related to weekly MTX use was substantial. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years
In conclusion, secukinumab is a largely safe and effective treatment for radiographic and non-radiographic axSpA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study
ConclusionsThe introduction of subsidized TNFi therapy did not change all-cause hospital admission or ED visit rates for existing AS patients. Whether the significantly increased direct health care costs are offset by reductions in other health care costs remains to be determined. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
A Response to: Letter to the Editor Regarding A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- α Inhibitors: The NETWORK-004 Prospective Observational Study
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
Correction to: The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model
(Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 1, 2022 Category: Rheumatology Source Type: research
